Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial

[1]  C. Dupuis,et al.  Monitoring of circulating monocyte HLA-DR expression in a large cohort of intensive care patients: relation with secondary infections , 2022, Annals of Intensive Care.

[2]  P. Pickkers,et al.  Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series , 2019, BMC Infectious Diseases.

[3]  I. Agache,et al.  Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases , 2019, The Journal of clinical investigation.

[4]  Peter Nürnberg,et al.  Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. , 2017, The Lancet. Respiratory medicine.

[5]  S. Orfanos,et al.  Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis , 2017, BMC Medicine.

[6]  Anna Rautanen,et al.  Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study , 2016, The Lancet. Respiratory medicine.

[7]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[8]  Richard L. Amdur,et al.  Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial* , 2016, Critical care medicine.

[9]  C. Wouters,et al.  Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients , 2014, Arthritis & rheumatology.

[10]  G. Hejblum,et al.  Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome , 2014, Arthritis & rheumatology.

[11]  F. Venet,et al.  Correction: Identification of Biomarkers of Response to IFNg during Endotoxin Tolerance: Application to Septic Shock , 2013, PLoS ONE.

[12]  Y. Shoenfeld,et al.  The Hyperferritinemic Syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome , 2013, BMC Medicine.

[13]  R. Hotchkiss,et al.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. , 2013, The Lancet. Infectious diseases.

[14]  L. Joosten,et al.  Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. , 2012, American journal of respiratory and critical care medicine.

[15]  A. Ayala,et al.  Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: Correlation with severity and secondary septic shock , 2007, Critical care medicine.

[16]  John C Marshall,et al.  The surviving sepsis campaign. , 2006, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[17]  N. Voirin,et al.  Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock , 2006, Intensive Care Medicine.

[18]  Jonathan Cohen,et al.  The International Sepsis Forum Consensus Conference on Definitions of Infection in the Intensive Care Unit , 2005, Critical care medicine.

[19]  S. Opal,et al.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. , 1997, Critical care medicine.

[20]  K. Asadullah,et al.  Monocyte deactivation in septic patients: Restoration by IFN-γ treatment , 1997, Nature Medicine.